BTNL8 Antibody (2187B) [Alexa Fluor® 647]

HEK293 human embryonic kidney cell line transfected with human BTNL8 and eGFP were stained with (A) Rabbit Anti-Human BTNL8 Alexa Fluor® 647-conjugated Monoclonal Antibody (Catalog # FAB9359R) or (B) Rabbit IgG Alexa Fluor® 647-conjugated isotype control antibody (Catalog # IC1051R). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow
• Clone: 2187B
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 647

BTNL8 Antibody (2187B) [Alexa Fluor® 647] Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: Human embryonic kidney cell line HEK-293-derived Human BTNL8
  Gln18-Lys238
  Accession # Q6UX41-1
• Specificity: Detects human BTNL8 in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for BTNL8 Antibody (2187B) [Alexa Fluor® 647]

• BTN9.2
• BTNL8
• butyrophilin-like 8
• butyrophilin-like protein 8
• UNQ702/PRO1347

Background

Butyrophilin-like 8 (BTNL8) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation (1). Human BTNL8 is a 500 amino acid (aa) type I transmembrane glycoprotein that contains a signal peptide followed by an extracellular domain (ECD), a transmembrane region and a short cytoplasmic domain (2). The ECD of human BTNL8 shares 88% sequence identity with the ECD of mouse BTNL8. BTNL8 has two alternatively spliced forms: B7-like and BTN-like. Both isoforms of BTNL8 are expressed in a range of human tissues (3). The complete immunological function of BTNL molecules is only beginning to emerge. BTNL8 has been shown to be important in initiation of primary immune responses, suggesting a role in priming of naïve T lymphocytes (3). Down-regulation of BNTL8 mRNA levels has been associated with ulcerative colitis and colon cancer (4). BTNL8 are expressed in colon, lung, testis and neutrophils, and its expression is significantly decreased in ulcerative colitis, colonic tumors as compared to unaffected tissue (4). Soluble BTNL8-Fc fusion protein binds to resting, but not activated T cells. In vitro, BTNL8 co-stimulates T cell proliferation and cytokine production. In vivo injections of BTNL8-Fc significantly increases production of
Ag-specific IgG during the primary but not the secondary immune response (3).

1. Arnett, H.A. et al. (2007) J. Immunol. 178:1523.
2. Arnett, H.A. et al. (2009) Cytokine 46:370.
3. Chapoval, A.I. et al. (2013) Mol Immunol. 56:819.
4. Lebrero-Fernández C. et al. (2016) Immun Inflamm Dis. 4:191.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q6UX41-1()